Newsletter Anmeldung

Newsletter Subscription

LDC and Cumulus Oncology Announce Collaboration

The Lead Discovery Center GmbH (LDC) and Cumulus Oncology announce the signing of a collaboration agreement enabling the two organisations to accelerate the discovery and development of novel oncology therapies.

The collaboration builds on the complementary expertise of both organisations. LDC contributes a proven track record in drug discovery and a team of scientists with the expertise and the deep insights necessary to develop assets modulating a range of oncology targets derived from its large academic network. Cumulus Oncology brings a team of successful life science entrepreneurs with a recognised track record in translational oncology drug development, as well as oncologists, scientists and pharma sector business professionals.

This collaboration is based around the reciprocal contribution of each group and the motivation to develop a growing portfolio of small molecule and biological assets with exceptional medical and commercial potential. Each party provides targets and assets in the oncology area for collaboration and potential future company co-creation as well as bringing a wider access to funding partners and collaborators globally.

“We anticipate that joining forces with Cumulus Oncology will leverage early-stage novel oncology approaches from our research networks, turning these early-stage assets into true innovations in cancer research and therapies”, stated Bert Klebl, CEO and CSO of the LDC. “This strategic partnership with one of the leading drug discovery centres in Europe provides a unique opportunity for Cumulus Oncology to fuel its pipeline of next generation novel oncology assets” said Alan Wise, Chairman of Cumulus Oncology.
“We are very much looking forward to working with our colleagues at LDC to the mutual benefit of both our organisations and ultimately to the benefit of the cancer research community, most especially, the patients dealing with a cancer diagnosis” added Clare Wareing, Founder and CEO of Cumulus Oncology.


​Further information.